A phase 3 randomized trial found that Mim8 prophylaxis significantly reduced bleeding rates compared with on-demand therapy and clotting factor prophylaxis in patients with hemophilia A with or without...
In 6-year long-term follow-up of adults with severe or moderately severe hemophilia B, single-dose fidanacogene elaparvovec maintained FIX activity and low treated annualized bleeding rates.
